Merck's Keytruda nabs 2nd approval in 2 days, this time in non-Hodgkin lymphoma

Merck’s Keytruda nabs 2nd approval in 2 days, this time in non-Hodgkin lymphoma

With Keytruda’s latest OK, Merck became the only immuno-oncology drugmaker that can flaunt an approval in primary mediastinal large B-cell lymphoma, which develops when abnormal white blood cells build up between the lungs and the breast bone. And the New Jersey pharma can say the same with cervical cancer, too. Click here to view original[…]

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

An important takeaway to come out of the American Society of Clinical Oncology conference early this month is that Merck’s lung cancer-fighting drug Keytruda is quite similar in its efficacy and safety to Bristol-Myers Squibb Co’s (NYSE:BY) Opdivo. This insight is the view of two attendees at the ASCO […] Click here to view original[…]

PARP battle heats up as Pfizer nabs priority review for talazoparib in breast cancer

PARP battle heats up as Pfizer nabs priority review for talazoparib in breast cancer

Last year at this time, Pfizer’s $14 billion purchase of Medivation was being cited as a cautionary tale of M&A gone wrong, after one product of that deal—prostate cancer drug Xtandi—turned in disappointing data at the annual confab of the American Society of Clinical Oncology (ASCO). Pfizer also paid top dollar for Medivation for its[…]

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?

Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual meeting, it rolled out data to support that notion. Click here to view original web page at www.fiercepharma.com

A 2-pronged attack could improve targeted therapies for colon cancer

A 2-pronged attack could improve targeted therapies for colon cancer

Two pathways have long been of interest to researchers studying colon cancer: Notch and MAPK. But drugs designed to target either pathway have proven disappointing. Now a team of researchers in Germany has made a discovery that sheds light on those disappointments—and provides insight that could improve colon cancer treatment. Click here to view original[…]